中国全科医学2017，Vol.20Issue(8)：1009-1014,6.DOI:10.3969/j.issn.1007-9572.2017.08.025
胰高血糖素样肽1抗动脉粥样硬化作用及其机制的研究进展
Research Progress of Anti-atherosclerotic Effects and Mechanism of Glucagon Like Peptide-1
杨光 1李青松 2成宪武1
作者信息
- 1. 133000吉林省延吉市,延边大学附属医院心内科
- 2. 133000吉林省延吉市,延边大学附属医院骨科
- 折叠
摘要
Abstract
Glucagon-like peptide-1 (GLP-1) is a kind of incretin,which can promote secretion of insulin into blood (a releasing process of glucose dependent),inhibit glucagon secretion,significantly lower blood sugar levels in patients with type 2 diabetes,and play a role in maintaining blood sugar stability and reducing the risk of hypoglycemia.The nonhypoglycemic effect of GLP-1 has received much attention in recent years.Animal and clinical studies have shown that besides the biological functions of regulating blood sugar and protecting pancreatic β cells of GLP-1,it can also protect the vascular endothelium,regulate a variety of inflammatory factors and chemokines,and show the anti-inflammatory effects,moreover,it plays a positive role in reducing multiple cardiovascular risk factors such as blood sugar,blood lipids,blood pressure and body weight.This suggests that GLP-1 has a potential value in the effect of anti-atherosclerosis.Based on the latest theoretical and clinical research results,the paper reviews the studies on the anti-atherosclerosis effects and its mechanism of GLP-1.关键词
胰高血糖素样肽1/动脉粥样硬化/综述Key words
Glucagon-like peptide 1/Atherosclerosis/Review分类
医药卫生引用本文复制引用
杨光,李青松,成宪武..胰高血糖素样肽1抗动脉粥样硬化作用及其机制的研究进展[J].中国全科医学,2017,20(8):1009-1014,6.
